A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

Non-Alcoholic Steatohepatitis Clinical Trial

Official title:

A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02571192
• Other study ID #: SHP626-102
• Status: Completed
• Phase: Phase 1
• Start date: October 1, 2015
• Est. completion date: October 1, 2015

Study information

• Verified date: April 2019
• Source: Mirum Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: October 1, 2015
• Est. primary completion date: October 1, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Age between 18 and 50 years, inclusive, at the time of consent.

2. Must be considered healthy. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, thyroid panel (includes T3, T4 and TSH at Screening only), blood chemistry, coagulation and urinalysis

3. Must have a body mass index between 18.0-30.0kg/m² inclusive with a body weight >50 kg (110 lbs).

4. Ability to swallow all investigational product.

5. A minimum of 1 bowel movement per day.

Exclusion Criteria:

1. History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gallbladder removal, gastric bypass surgery, ileal resection, any small intestinal resection,or current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments.

2. Current or relevant history of physical or psychiatric illness.

3. Known or suspected intolerance or hypersensitivity to the investigational product, or closely-related compounds, or any of the stated ingredients.

4. Significant illness, as judged by the investigator, within 2 weeks of the dose of investigational product.

5. Known history of alcohol or other substance abuse within the last year.

6. Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to the dose of investigational product.

7. Within 30 days prior to the dose of investigational product:

• Have used an investigational product (if elimination half-life is <6 days, otherwise 5 half-lives).

• Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.

• Have had any substantial changes in eating habits, as assessed by the investigator.

8. Confirmed systolic blood pressure >139mmHg or <89mmHg, and diastolic blood pressure >89mmHg or <49mmHg.

9. Twelve-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject's eligibility.

10. A positive screen for drugs of abuse at Screening or a positive screen for alcohol or drugs of abuse at Check-in (Day -1).

11. Male subjects who consume more than 21 units of alcohol per week or 3 units of alcohol per day.

12. A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen, or hepatitis C virus antibody screen.

13. Use of tobacco in any form

14. Routine consumption of more than 2 units of caffeine per day

15. Current use of any medication including over-the-counter, herbal, or homeopathic preparations

16. An inability to follow a standardized diet and meal schedule or inability to fast

17. Have participated in a [14C]-study within the last 6 months prior to the dose of investigational product.

18. Exposure to clinically significant radiation within 12 months prior to the dose of investigational product

Related Conditions & MeSH terms

• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• Non-Alcoholic Steatohepatitis

Intervention

Drug:
• SHP626
single oral dose 50mg SHP626 with approximately 5.95 µCi RAD

Radiation:
• 5.95 µCi RAD

Locations

Country	Name	City	State
United States	Covance Madison Clinical Research Unit	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Mirum Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic parameters will be determined from the plasma and blood concentration time data of total radioactivity and from the plasma concentration-time data for SHP626 by non-compartmental analysis.		Day 1 to day 10
Primary	Total radioactivity (RAD) in whole blood and plasma		Day 1 to day 10
Primary	To determine the total RAD in urine and feces.		Day 1 to day 10
Primary	Maximum plasma concentration (Cmax) of 50mg [14C]-SHP626 and RAD occurring at time of maximum observed concentration (tmax)		Day 1 to day 10
Primary	Area under the plasma concentration curve (AUC0-t) of 50mg [14C]-SHP626 and RAD from the time of dosing to the last measurable concentration		Day 1 to Day 10
Primary	Area under the plasma concentration curve (AUC0-8 ) of 50mg [14C]-SHP626 and RAD extrapolated to infinity, calculated using the observed value of the last non-zero plasma concentration		Day 1 to Day 10
Primary	First order rate constant associated with the terminal portion of the plasma curve terminal half-life (t½) for 50mg [14C]-SHP626 and RAD		Day 1 to Day 10
Primary	Total body clearance (CL/F ) of 50mg [14C]-SHP626 and RAD for extravascular administration divided by the fraction of dose absorbed		Day 1-10
Primary	Volume of distribution (Vz/F ) of 50mg [14C]-SHP626 and RAD associated with the terminal slope following extra-vascular administration divided by the fraction of dose absorbed		Day 1-10
Primary	Cumulative amount (Aef )of RAD recovered in stool over the dosing interval		Day 1-10
Primary	Excreted Percent of RAD recovered in stool over the dosing interval		Day 1-10
Primary	Cumulative amount (Aeu ) of RAD recovered in urine over the dosing interval		Day 1-10
Primary	Excreted Percent of RAD recovered in urine over the dosing interval		Day 1-10
Primary	Renal Clearance (CLR ) of 50mg [14C]-SHP626		Day 1 -10
Secondary	Characterize and identify metabolites of [14C]-SHP626 in plasma by accelerator mass spectrometry for radioactivity quantification	Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary	Day 1 to day 10
Secondary	Characterize and identify metabolites of [14C]-SHP626 in urine by accelerator mass spectrometry for radioactivity quantification	Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary	Day 1 to day 10
Secondary	Characterize and identify metabolites of [14C]-SHP626 in feces by liquid scintillation counting	Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary	Day 1 to day 10
Secondary	Assess the safety and tolerability of [14C]-SHP626 by adverse events (AEs) defined as changes, including changes from baseline in physical examination findings	AEs will be coded using the agreed upon version of MedDRA. The number of events, incidence, and percentage of TEAEs will be calculated overall, by system organ class and by preferred term. TEAEs will be further summarized by severity and relationship to investigational product. AEs related to investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly summarized/listed.	Screening to day 7
Secondary	Changes from baseline in vital signs		Screening to day 7
Secondary	Changes from baseline in ECGs		Screening to day 7
Secondary	Changes from baseline in hematology		Screening to day 7
Secondary	Changes from baseline in coagulation		Screening to day 7
Secondary	Changes in baseline in urinalysis		Screening to day 7
Secondary	Changes in baseline in chemistry		Screening to day 7